BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end
BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in...
Source: proactiveinvestors.com